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Abstract
Introduction: HIV and cervical cancer are intersecting epidemics that disproportionately affect one of the most vulnerable
populations in the world: women in low- and middle-income countries (LMICs). Historically, the disparity in cervical cancer risk
for women in LMICs has been due to the lack of organized screening and prevention programmes. In recent years, this risk has
been augmented by the severity of the HIV epidemic in LMICs. HIV-positive women are at increased risk for developing cervical
precancer and cancer, and while the introduction of antiretroviral therapy has dramatically improved life expectancies among
HIV-positive women it has not been shown to improve cancer-related outcomes. Therefore, an increasing number of HIV-positive
women are living in LMICs with limited or no access to cervical cancer screening programmes. In this commentary, we describe
the gaps in cervical cancer prevention, the state of evidence for integrating cervical cancer prevention into HIV programmes and
future directions for programme implementation and research.
Discussion: Despite the biologic, behavioural and demographic overlap between HIV and cervical cancer, cervical cancer
prevention has for the most part been left out of sexual and reproductive health (SRH) services for HIV-positive women. Lower
cost primary and secondary prevention strategies for cervical cancer are becoming more widely available in LMICs, with
increasing evidence for their efficacy and cost-effectiveness. Going forward, cervical cancer prevention must be considered a
part of the essential package of SRH services for HIV-positive women. Effective cervical cancer prevention programmes will
require a coordinated response from international policymakers and funders, national governments and community leaders.
Leveraging the improvements in healthcare infrastructure created by the response to the global HIV epidemic through
integration of services may be an effective way to make an impact to prevent cervical cancer among HIV-positive women, but
more work remains to determine optimal approaches.
Conclusions: Cervical cancer prevention is an essential part of comprehensive HIV care. In order to ensure maximal impact
and cost-effectiveness, implementation strategies for screening programmes must be adapted and rigorously evaluated through
a framework that includes equal participation with policymakers, programme planners and key stakeholders in the target
communities.
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Introduction
The combined threat that cervical cancer and HIV present
to women’s quality of life, reproductive capacity and overall
mortality highlights a glaring inequality in global women’s
health. The enormous international disparity in the incidence
of and survival from cervical cancer has historically aligned
most closely with country income [1]. Nearly 85% of cases
and 87% of deaths occur in less developed regions, where
several factors conspire to make cervical cancer a leading
cause of cancer and cancer-related mortality [2]. Inadequate
healthcare and public health infrastructure, competing health
priorities and persistent poverty prevent large-scale cervical
cancer prevention programmes from gaining traction, resulting
in only a small minority of the population being screened
[3]. Rates of cervical cancer in less developed countries
are similar to those seen in the United States prior to the
introduction of widespread screening [4].
In the last 20 years, the increased burden of cervical cancer
has been intensified by the contribution of HIV to cervical
precancer and cancer. Global maps showing country-specific
HIV prevalence match the global maps of cervical cancer
incidence and mortality. For example, the incidence of cervical
cancer is 42.7 per 100,000 women in Eastern Africa, a high
HIV-prevalence region with low screening coverage, compared
to 30.6/100,000 in Middle Africa (moderate HIV prevalence,
low screening) and 6.6/100,000 in Northern Africa (low HIV
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prevalence, moderate screening coverage) [5]. The high rate
of HIV infection in many low- and middle-income countries
(LMICs) has potentiated the already increased risk for cervical
cancer for women living in these countries. The decrease in
cellular immunity caused by HIV increases the risk for new
and persistent human papillomavirus (HPV) infections  the
primary cause of cervical cancers and precancerous cervical
lesions  and contributes to an accelerated incidence and
progression of cervical neoplasia [6,7].
Increased availability of HIV care and treatment, com-
bined with greater coverage of antiretroviral therapy (ART)
in recent years, has been lifesaving for entire populations
of HIV-positive women. In contrast to other AIDS-related
malignancies, which show improvement with ART, the positive
effect of ART on cervical cancer outcomes is not clear [811].
Conversely, researchers have shown that the risk of anal
cancer, another HPV-related malignancy, actually increases
after ART use, making it plausible that the biologic risk for
cervical cancer may increase [12]. Regardless of the direct
biologic effect of ART on cervical cancer risk, in the many
LMICs that have addressed their high HIV prevalence through
improved HIV testing and access to treatment, there is a
significant increase in the number of HIV-positive women
living longer with excess cervical cancer risk [13]. This makes
the implementation of effective screening programmes an
urgent public health priority, especially for the HIV-positive
women who are most vulnerable to the disease.
There is a precedent of successful partnerships between
international donors and local governments to strengthen
healthcare infrastructure and build local capacity in ways
that helped to stem the HIV epidemic. Many government
health systems have successfully leveraged these gains in the
healthcare system and numbers of trained healthcare work-
ers to address other healthcare needs such as tuberculosis,
malaria, family planning, maternal health and other non-
communicable diseases (NCDs) [1416]. As evidence for the
efficacy and cost-effectiveness of integrating these other
health services increases, there has been an increase in
donor funding and policy commitment to support integra-
tion. However, cervical cancer is routinely excluded from
the definition of sexual and reproductive health (SRH)
services, which often focus on family planning, prevention
of maternal-to-child transmission (PMTCT) of HIV and
sexually transmitted infection (STI) prevention [1720].While
the World Health Organization (WHO) 2006 Guidelines on
Sexual and Reproductive Health for Women Living with HIV
do include cervical cancer screening as a topic area, inclusion
of cervical cancer prevention as part of essential services for
HIV-positive women is not a focus of that document. Rather,
the section on cervical cancer concludes with recommenda-
tions for HIV-positive women to have the same access
to cervical cancer screening as HIV-negative women [21].
As research into integration of reproductive health and HIV
services evolved, more recent documents that focus on
provision of comprehensive care for people living with HIV in
LMICs include recommendations on how to integrate family
planning, STI prevention and PMTCT, while cervical cancer
is not mentioned [22,23]. The global health community is
failing women in a crucial way: it has neglected prevention,
screening and treatment for cervical cancer among the highest
risk population, HIV-positive women in LMICs. In this com-
mentary, we describe the current policy and evidence around
strategies for implementing cervical cancer into HIV care and
recommend future research and policy directions to ensure
that cervical cancer prevention is included as part of essential
SRH services for HIV-positive women.
Discussion
There are several reasons for the exclusion of cervical cancer
as part of comprehensive care for women living with HIV.
Primarily, the majority of the world’s HIV-positive women
live in countries where there is no access to cervical cancer
prevention for anyone, regardless of their serostatus. One
of the effects of this lack of screening infrastructure is an
absence of cancer registries in most LMICs. Without accurate
estimates of the number of cases each year and the impact of
HIV on the incidence and prevalence of cervical cancer, it
is impossible to set targets and track progress in addressing
this issue. Another reason for the exclusion of cervical cancer
from SRH services offered to HIV-positive women is that,
despite being caused by an infectious agent, it is often con-
ceptualized as an NCD, rather than a component of SRH.
Instead of receiving increased attention by having a home in
two different content areas, this dual identity has actually led
to less focus and attention for cervical cancer prevention,
which is often seen as not fully belonging in either category.
As the immediate and pressing needs of the HIV epidemic
have begun to abate, there is an opportunity to use the
lessons from both NCD and SRH management to address
cervical cancer prevention in a way that best fits the unique
characteristics of the disease.
Cervical cancer prevention fits into an NCD paradigm of
integrating preventative care into existing clinics through
periodic, evidence-based screening, with treatment of early
or preclinical disease. Importantly, though, because of the
counselling, outreach, screening techniques and fertility
implications for treatment of invasive disease, cervical cancer
prevention has a natural place in SRH services. Providers who
are more comfortable talking to women about their repro-
ductive health and family planning, and who can ably counsel
women and perform pelvic exams, may be better suited to
perform cervical cancer screening [24]. A successful cervical
cancer prevention programme should include elements from
NCD prevention strategies (disease awareness, coupled with
periodic, universal screening and access to risk-reduction
interventions) when providing services under the paradigm
of reproductive health.
Another key reason for the exclusion of cervical cancer
from primary healthcare in LMICs, and more recently from
comprehensive HIV care, was the lack of feasible and
affordable prevention strategies. We now have a wide range
of low-cost and effective primary and secondary prevention
options that can be operationalized in LMICs, making dramatic
global reductions in cervical cancer incidence a realistic goal
within a generation. HPV vaccination is the most successful
and cost-effective strategy for cervical cancer prevention,
especially in high HIV-prevalence areas [2527]. The WHO has
prequalified two HPV vaccines that could dramatically reduce
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cervical cancer deaths in LMICs if vaccination coverage can be
scaled up [28]. GAVI, the Global Vaccine Alliance, is supporting
initiatives to provide vaccines in selected LMICs, and pilot
delivery programmes are ongoing [29]. The vaccination of
adolescent girls also provides an opportunity to provide them
with other reproductive health services and health education
(including family planning and menstrual hygiene); it would
provide primary prevention of HPV and cervical cancer prior
to sexual exposure to HIV. Ensuring that adolescent girls have
the opportunity to receive a vaccine that protects them from
the morbidity and mortality related to cervical cancer should
be a key global health priority.
Conventional screening methods, using Pap smears and
biopsies, require infrastructure and clinical expertise and are
hard to scale up in LMICs. However simpler, cheaper screening
techniques, such as visual inspection with acetic acid (VIA)
and HPV DNA testing, hold great promise and are under-
going widespread evaluation [30,31]. The WHO Global Action
Plan on NCDs describes screening with VIA as a ‘‘best buy,’’
meaning that it is both highly cost effective (i.e. it costs less
than the per capita gross domestic product to avert one
disability adjusted life-year) and it is feasible to implement
in settings with constrained health systems [32]. There
are promising results from large trials, suggesting that VIA
can reduce cervical cancer incidence by 25 to 30% [33],
with similar performance characteristics among HIV-positive
women compared to HIV-negative women [34]. Although
screening with HPV is more expensive than with VIA, a study
by Goldie et al. [35] in five LMICs found that HPV screening
is very cost-effective, and a single test at age 35 years reduces
lifetime cancer risk by 25 to 36%. This finding has been
supported in models of HPV screening among HIV-positive
women [36]. Ongoing and completed studies are looking
at novel strategies to maximize uptake of HPV screening,
including self-collection and community health campaign
models, in low-resource/high HIV-prevalence settings [37,38].
The WHO has recognized and summarized the evidence
for low-cost cervical cancer prevention strategies in their
2013 Comprehensive Cervical Cancer Prevention and Control
Manual [39], which includes recommendations for screening
strategies for HIV-positive women.
One strategy for ensuring that HIV-positive women access
cervical cancer screening and prevention is through service
integration. Integrating care for HIV, sexual health, reproduc-
tive health and maternal health has been shown to improve
uptake of services, reduce HIV-related stigma and improve
the quality of care received by women [40,41]. Although
there are many definitions of integration, the model that is
most feasible for cervical cancer and HIV care is integration of
cervical cancer services into existing HIV-care programmes,
given the lack of standalone cervical cancer prevention clinics
and periodicity of screening. There is growing evidence for
the feasibility of integrating cervical cancer prevention into
HIV services using low-cost screening strategies coupled with
treatment for precancerous lesions [4245]. Furthermore,
integrating cervical cancer prevention services into HIVprimary-
care facilities, rather than referring women to a separate
family planning or reproductive health facility, provides an
opportunity to include and educate male partners, which may
be particularly important in areas where men have control
over healthcare decisions [46,47].
However, integration may not be feasible or successful in
all settings. While integration holds the promise of leveraging
stronger health systems to improve access to and uptake
of secondary services in higher risk populations through a
decrease in the visit burden and loss to follow-up, several
studies in sub-Saharan Africa have shown significant weak-
nesses in models of various health services integrated into
HIV care. These include limited interest among the general
population in receiving care through integrated models [41],
concerns about disclosure and resultant stigma in general
outpatient settings [40], lack of clear policies, unacceptable
clinical load on the staff, longer wait times and concerns
about quality of care [48].
While the promise of integration has not been borne out in
every setting, this does not mean that it should be discarded
for the next big idea in service delivery. One randomized study
of integrated HIV and antenatal services showed high rates
of attrition in both arms, suggesting that there are structural
barriers to uptake that lie outside of the care model [49]. This
finding, along with the difficulties experienced in different
settings, speaks to the need for community-driven, context-
specific adaptation of the evidence-proven interventions for
cervical cancer prevention, specifically VIA, HPV testing and
‘‘see and treat’’ strategies. While the efficacy and effective-
ness of these low-cost strategies have been clearly shown in
large, well-conducted trials, there are few implementation
studies done in partnership with target communities to adapt
and iteratively evaluate the effectiveness of the resulting
intervention and implementation strategy. Implementation
and dissemination science, or ‘‘the scientific study of methods
to promote the systematic uptake of research findings and
other evidence-based practices into routine practice, and
hence, to improve the quality and effectiveness of health
services and care,’’ provides tools to bridge the gap between
scientific evidence and public health practices and policy.
In addition to the standard clinical effectiveness outcomes,
implementation studies evaluate a combination of quan-
titative, qualitative and process measures to evaluate the
feasibility and sustainability of the implementation, essen-
tially exploring and explaining the individual, interpersonal,
community and policy-level factors necessary for the success
of evidence-based interventions. The above-cited studies of
self-collected HPV in Uganda and Kenya are examples of using
implementation science research to address the gap between
evidence-based cervical cancer prevention, policy and uptake.
Conclusions
HIV and cervical cancer are intersecting epidemics that dispro-
portionately affect one of the most vulnerable populations in
the world: women in LMICs. Despite the biologic, behavioural
and demographic overlap, cervical cancer prevention has
for the most part been left out of SRH services for HIV-positive
women. Similar to the coordinated and multilateral response
to the HIV epidemic, an effective programme for cervical
cancer prevention among HIV-positive women needs inter-
national, national and community leadership for a broad-
based and sustainable response. International guidelines
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for HIV care in LMICs must include a mandate to provide
cervical cancer prevention as part of comprehensive SRH care.
Funding agencies and local governments must then consider
this a key component of HIV care and provide the funding,
training, support supervision and accountability necessary to
ensure maximal coverage of services. Implementation studies
done in partnership with local governments, key stakeholders
and programmes providing HIV care will facilitate cervical
cancer prevention strategies that are not only included as
part of the essential package of services, but are provided
in a context-specific way. Cervical cancer prevention has the
potential to be effective, sustainable and cost-effective. A
crucial part of the implementation strategy will be developing
a monitoring and evaluation programme to measure the
coverage and quality of cervical cancer prevention services
provided as part of comprehensive SRH services for HIV-
positive women.
The climate is right for a coordinated response to the dual
threat posed by HIV and cervical cancer in LMICs: low-cost
strategies, improved health infrastructure and engagement
in the healthcare system by a high-risk population. The ability
to impact this long-standing global health disparity is well
within our reach.
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